XmAb942 (Xtend™ TL1A)
Novel high-potency anti-TL1A antibody designed for extended half-life, in Phase 1 development for the treatment of patients with IBD
XmAb942 is a monospecific anti-TL1A antibody, utilizing Xencor’s Xtend™ Fc Domain and proprietary Fc silencing technology, with potentially class-leading potency, and is under development for patients with inflammatory bowel diseases (IBD). The two most common forms of IBD are Crohn’s disease and ulcerative colitis (UC).
Xencor announced final results from the Phase 1 study of XmAb942 in healthy volunteers and provided a TL1A pipeline update in May 2026. (R&D Update, May 5, 2026)
Xencor is conducting the global XENITH-UC Study, a Phase 2b study of XmAb942 in UC. XENITH-UC is a randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe UC, whose disease has progressed after at least one conventional or advanced therapy.